Received 23 April 2009/Returned for modification 10 June 2009/Accepted 15 June 2009
|
|
- Basil Armstrong
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2009, p Vol. 53, No /09/$ doi: /aac Copyright 2009, American Society for Microbiology. All Rights Reserved. In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences Marieke Vermeersch, 1 Raquel Inocêncio da Luz, 1 Kim Toté, 1 Jean-Pierre Timmermans, 2 Paul Cos, 1 and Louis Maes 1 * Laboratory of Microbiology, Parasitology, and Hygiene (LMPH) 1 and Laboratory of Cell Biology and Histology, 2 Faculty of Pharmaceutical, Biomedical, and Veterinary Sciences, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium Received 23 April 2009/Returned for modification 10 June 2009/Accepted 15 June 2009 The in vitro susceptibilities of the reference strain Leishmania donovani MHOM/ET/67/L82 to sodium stibogluconate, amphotericin B, miltefosine, and the experimental compound PX-6518 were determined for extracellular log-phase promastigotes, established axenic, fresh spleen-derived, and intracellular in primary mouse peritoneal macrophages. Susceptibility to amphotericin B did not differ across the various axenic models (50% inhibitory concentrations [IC 50 ], 0.6 to 0.7 M), and amphotericin B showed slightly higher potency against intracellular (IC 50, 0.1 to 0.4 M). A similar trend was observed for miltefosine, with comparable efficacies against the extracellular (IC 50, 0.4 to 3.8 M) and intracellular (IC 50, 0.9 to 4.3 M) stages. Sodium stibogluconate, used either as Pentostam or as a crystalline substance, was inactive against all axenic stages (IC 50, >64 g Sb V /ml) but showed good efficacy against intracellular (IC 50,22to28 g Sb V /ml); the crystalline substance was about two to three times more potent (IC 50,9to11 g Sb V /ml). The activity profile of PX-6518 was comparable to that of sodium stibogluconate, but at a much higher potency (IC 50, 0.1 g/ml). In conclusion, the differential susceptibility determines which in vitro models are appropriate for either drug screening or resistance monitoring of clinical field isolates. Despite the more complex and labor-intensive protocol, the current results support the intracellular amastigote model as the gold standard for in vitro Leishmania drug discovery research and for evaluation of the resistance of field strains, since it also includes host cell-mediated effects. Axenic systems can be recommended only for compounds for which no cellular mechanisms are involved, for example, amphotericin B and miltefosine. Downloaded from Current first-line chemotherapy of leishmaniasis relies on a rather limited arsenal of drugs including sodium stibogluconate, meglumine antimoniate, amphotericin B, and miltefosine, but these entail either problems of emerging resistance, severe side effects, or high costs (5). Since vaccines are not yet on the horizon (23), maintenance and improvement of existing treatment regimens, combined with new drug discovery initiatives, appear to be the only ways to guarantee continued control of this important tropical disease (3, 11, 27). Both for drug screening and for determination of the susceptibility of field strains, different laboratory methods are being used that focus on the promastigote, the axenic amastigote, or the intracellular amastigote stage. However, it remains unclear how these models cross-validate each other. The differences in environmental conditions between promastigotes and in vivo are reflected in their needs for in vitro cultivation. While promastigotes are easily cultured in suspension (8), are more difficult to maintain in vitro, since they require macrophages as host cells to meet the highly acidic intracellular environment (15). Cultivation of axenic in suspension has * Corresponding author. Mailing address: Laboratory for Microbiology, Parasitology, and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical, and Veterinary Sciences, Antwerp University, Groenenborgerlaan 171, B-2020 Antwerp, Belgium. Phone: Fax: louis.maes@ua.ac.be. Published ahead of print on 22 June been successful, enabling promising new opportunities for drug screening and mode-of-action studies (31, 38). For field strains, infection of macrophages with metacyclic promastigotes is generally used but is subject to a high degree of variability in infectivity depending on the growth characteristics of the isolate and the level of in vitro metacyclogenesis (6). Despite the large body of literature on the subject, the central question remains which laboratory system is optimally suited for either drug-screening purposes or field strain susceptibility testing against the current firstline antileishmanial drugs. The aim of the present study was to compare the different in vitro test systems and the intrinsic susceptibilities of the various stages of a single reference strain of Leishmania donovani (MHOM/ET/67/L82) to pentavalent antimony (Sb V ), amphotericin B, miltefosine, and the experimental antileishmanial lead compound PX-6518, a saponin mixture isolated from the Vietnamese plant Maesa balansae (19) and included in the test to underline the importance of current findings for drugscreening and mode-of-action studies. To our knowledge, this is a first report on the in vitro sensitivities of all Leishmania stages (including freshly collected ex vivo ) to a broad range of standard reference drugs in a single integrated experimental setup. MATERIALS AND METHODS Culture media, products, reagents, and animals. Adenosine, folic acid, D- biotin, hemin, NaHCO 3, potato starch, dimethyl sulfoxide, Giemsa stain, and on March 16, 2016 by guest 3855
2 3856 VERMEERSCH ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. IC 50 s of antileishmanial reference compounds against extracellular stages a and intracellular of L. donovani MHOM/ ET/67/L82 in PMM after infection with either promastigotes, axenic, or ex vivo Reference compound (unit) Log-phase promastigotes Axenic evaluation model Axenic IC 50 (mean SD for at least 6 replicates) Ex vivo Metacyclic promastigotes Cellular (PMM) evaluation model Axenic Ex vivo Cytotoxicity (MRC-5 cells) Amphotericin B ( M) Miltefosine ( M) PX-6518 ( g/ml) Pentostam ( g/ml) Sb V ( g/ml) a Promastigotes, axenic, and ex vivo. resazurin were purchased from Sigma, whereas minimal essential medium (MEM), RPMI-1640 medium, L-glutamine, fetal calf serum (FCS), and trypsin- EDTA (0.25%) were supplied by Invitrogen. The powder form of sodium stibogluconate and the marketed injectable formulation Pentostam (GSK) were included along with miltefosine (pure crystalline compound obtained from WHO-TDR) and amphotericin B-deoxycholate (Fungizone; Squibb). The experimental drug PX-6518 was available from previous investigations (19). Golden hamsters and Swiss mice were supplied by Janvier (France). Animal experiments were approved by the ethical committee of the University of Antwerp. Parasite and cell cultures. Leishmania donovani MHOM/ET/67/L82 (also known as LV9 or HU3) was obtained as a cryostabilate from the Institute of Tropical Medicine in Antwerp, Belgium, and was used to infect golden hamsters serving as donor animals. The adapted axenic amastigote culture of the same strain was obtained from the Swiss Tropical Institute and further maintained in Schneider s medium. For the specific purpose of this experiment, the axenic were converted back to promastigotes and were maintained in MEM supplemented with 200 mm L-glutamine, 16.5 mm NaHCO 3, 10% heat-inactivated FCS, 40 mg/liter adenine, 3 mg/liter folic acid, 2 mg/liter D-biotin, and 2.5 mg/liter hemin. Fresh ex vivo were purified from the spleen of a 6-week-infected donor hamster and were immediately kept at 37 C on acidic amastigote medium. Primary mouse peritoneal macrophages (PMM) were collected from Swiss mice 2 days after peritoneal stimulation with a 2% potato starch suspension. Cells were collected and grown in RPMI-1640 medium supplemented with 200 mm L-glutamine, 16.5 mm NaHCO 3 and 5% inactivated FCS. Human simian virus 40-immortalized lung fibroblasts (MRC-5 SV2) were obtained from the European Collection of Cell Cultures (United Kingdom) and maintained in MEM supplemented with 5% FCS and 1% L-glutamine. All amastigote cultures and assays and the cytotoxicity assay were conducted at 37 C under 5% CO 2. The promastigote cultures and assay mixtures were kept at 25 C under normal atmospheric conditions. Compound solutions/dilutions. Stock solutions of crystalline sodium stibogluconate (NaSb V [31.3% Sb V ]) were prepared in preheated phosphate-buffered saline at 37 C and were immediately used in the various tests. Pentostam (100 mg Sb V /ml), miltefosine, amphotericin B, and semipurified PX-6518 were dissolved/ diluted in MilliQ-water. All results with crystalline NaSb V and Pentostam are presented as Sb V g/ml equivalents. The stock solutions were kept at 20 C prior to use, except for miltefosin and Pentostam, which were stored at 4 C. For axenic tests, twofold serial dilutions of the reference drugs were spotted in 96-well flat-bottom microplates (Greiner) prior to addition of the biological test system. For intracellular amastigote tests, drugs were added after adhesion of macrophages and proper internalization of Leishmania stages. Therefore, dilutions were spotted in separate V-bottom plates, allowing easy transfer to the test plates after solubilization in 100 l culture medium. Axenic drug sensitivity assays. Assays were performed in sterile 96-well microtiter plates, with each well containing 10 l of the compound dilution and 200 l of parasite inoculum ( promastigotes/well or /well). Parasite multiplication was compared to that for untreated controls (100% growth) and uninfected controls (0% growth). After 72 h of incubation, resazurin was added and cell viability was measured fluorometrically (excitation, 550 nm; emission, 590 nm) (21, 34). The results were expressed as the percentage of reduction in the parasite burden compared to that in untreated control wells, and the 50% inhibitory concentration (IC 50 ) was calculated by Probit analysis. At least six independent replicates were performed for each observation. Intracellular drug sensitivity assays. PMM were seeded in 96-well microtiter plates at cells/well and were left for adhesion and differentiation for 48 h before infection with either promastigotes, axenic, or ex vivo. To assure optimal metacyclogenesis prior to infection, promastigotes were preconditioned for 24 h at 37 C in acidified promastigote medium (ph 5.4). For promastigotes, an infection ratio of 15 stages per macrophage was used. Since axenic and ex vivo tend to multiply slightly more extensively in PMM, the infection ratio was kept at 5. Compound dilutions were added 2 h after infection, except for promastigotes, which were left undisturbed for another 24 h to allow proper internalization and transformation into. At this stage, the medium was replaced to remove the noninternalized stages. After 5 days of incubation, total parasite burdens were microscopically assessed on Giemsa-stained wells and were compared to those for untreated infected controls. The results are expressed as the percentages of reduction in the parasite burden from that in wells with untreated infected controls, and the IC 50 s were calculated. At least six independent tests were performed for each observation. Electron microscopic studies. A small-scale ultrastructural study was performed with the knowledge that long-term cultivation of axenic may promote the reappearance of promastigote-like features (16, 24). Samples for transmission electron microscopy were obtained after centrifugation of extracellular stages or trypsinized PMM with intracellular stages, fixation in a 0.1 M sodium cacodylate-buffered (ph 7.4) 2.5% glutaraldehyde solution for 2 h, rinsing (three times, for 10 min each time) in 0.1 M sodium cacodylate-buffered (ph 7.4) 7.5% saccharose, and postfixation in 1% OsO 4 solution for 1 h. After dehydration in an ethanol gradient (70% ethanol [20 min], 96% ethanol [20 min], and 100% ethanol [twice, for 20 min each time]), samples were embedded in Durcupan ACM. Ultrathin sections were stained with uranyl acetate and lead citrate and were examined in a Philips CM 10 microscope at 80 kv. RESULTS In vitro susceptibility testing. The activity of amphotericin B did not differ much across the different models and stages (Table 1). Mean IC 50 s against axenic log-phase promastigotes, established axenic, and ex vivo ranged from 0.6 to 0.7 M. Slightly higher potency was observed against the intracellular amastigote stage (IC 50 s, 0.1 to 0.4 M), irrespective of the stages that were used for infection. A similar trend was observed for miltefosine, with almost comparable efficacies against the extracellular and intracellular stages; established axenic and ex vivo were slightly more sensitive (IC 50 s, 0.4 to 0.9 M). Pentostam and NaSb V were not active against promastigotes (IC 50, 64 g Sb V /ml), but surprisingly, no activity was observed against established axenic or freshly collected spleen-derived ex vivo (IC 50, 64 g Sb V / ml). Against intracellular, Pentostam yielded IC 50 s of 22 to 28 g Sb V /ml, although with a higher degree of variability among the different replicates. It is noteworthy that
3 VOL. 53, 2009 IN VITRO SUSCEPTIBILITIES OF LEISHMANIA STAGES 3857 TABLE 2. Suitability of different L. donovani in vitro laboratory models for drug screening and drug susceptibility determination Test system (L. donovani) Suitability a of laboratory in vitro model for: Drug screening Determination of susceptibility to the following drug b : AMB MILT Sb PX-6518 Log-phase promastigotes Established axenic NA NA NA NA Ex vivo axenic Intracellular a, suitable;, not suitable; NA, not applicable. b AMB, amphotericin B; MILT, miltefosine; Sb, antimony (Pentostam or Sb V ). crystalline NaSb V showed about a two- to threefold increase in potency, with IC 50 s ranging from 8.8 to 10.5 g Sb V /ml. Like Pentostam and NaSb V, PX-6518 showed no efficacy against promastigotes, established axenic, or ex vivo. A consistent, high activity was obtained against intracellular stages after infection with either axenic or ex vivo (IC 50, 0.1 g/ml). Infection with metacyclic promastigotes resulted in marginally lower efficacy (IC 50, 0.7 g/ml), which may reflect incomplete intracellular transformation of promastigotes into. The applicability of the different models for either drug screening or determination of the resistance of field strains is summarized in Table 2. Morphological evaluation. Specific attention was given to the established axenic in an attempt to ascertain whether the parasite stages were either amastigote-like or promastigote-like. Light microscopy showed amastigote-like organisms, i.e., clear, immobile, rounded stages with dense cell masses, about 2 m in diameter. However, ultrastructural characteristics indicated the presence of organisms that were more promastigote-like, i.e., more-oval cell bodies, the presence of a strong protruding flagellum, and the absence of megasomes (Fig. 1a and b). In contrast, fresh ex vivo and intracellular amastigote stages (Fig. 1c) did not possess flagella beyond the margins of the cell body, were clearly rounded, and exhibited structures resembling megasomes. DISCUSSION The Leishmania life cycle comprises different developmental stages, all of which have been used for either drug-screening purposes or determination of the resistance of field isolates. However, specific recommendations are needed depending on the experimental objective. To address this, the comparative in vitro sensitivities of all possible stages of a single L. donovani reference strain (MHOM/ET/67/L82) to all current first-line drugs and one experimental drug, PX-6518, were determined (Table 1). The main observation for all reference drugs was that logphase promastigotes tended to be less sensitive than the other extracellular or intracellular stages and were fully refractory to Sb V and PX These findings and the fact that promastigotes are the vector stage, differing considerably from the intracellular mammalian amastigote target, provide a convincing argument for excluding them for drug-screening purposes (Table 2). On the other hand, susceptibility to amphotericin B and miltefosine, which are known to affect membrane integrity directly or indirectly and which are able to exert antileishmanial action independently of cell-mediated parasiticidal mechanisms, has been clearly demonstrated (20, 26, 40). It is therefore not too speculative to propose that promastigotes could indeed be used for determination of the resistance of field isolates to amphotericin B and miltefosine (18, 25). This procedure will become particularly relevant for the large-scale monitoring of resistance to miltefosine in the Indian subcontinent, in view of its recent introduction as a first-line medication in the current Kala-Azar Elimination Program (36; WHO Regional Office for South-East Asia, meeting on guidelines and standard operating procedures for kala-azar elimination, Kolkata, India, 16 April 2007). FIG. 1. Ultrastructural details of in vitro-established axenic and intracellular. Shown are Leishmania donovani L82 axenic in cell-free medium (a and b) and 72 h after infection of PMM (c). Established axenic show oval cell bodies with a clear nucleus (n) and kinetoplast (k) and with flagella (f) protruding from the flagellar pocket. In contrast, intracellular axenic are more rounded and possess short flagella and megasome-like (m) structures.
4 3858 VERMEERSCH ET AL. ANTIMICROB. AGENTS CHEMOTHER. Established axenic have been positioned as an attractive alternative to the more complicated and labor-intensive cellular amastigote test in drug screening, but they obviously cannot be proposed for monitoring of the resistance of clinical field strains (Table 2). Publications on similarities between axenic and intracellular in terms of morphology, gene regulation, enzyme profile, and sensitivity to some reference drugs may strengthen the use of established axenic as a promising alternative drug-screening model (4, 9, 37). However, other investigators have drawn attention to marked differences between axenic and lesion-derived ex vivo or intracellular (17). In addition, long-term axenic cultivation may promote the reappearance of promastigote-like features, indicating the need for cautious use and continued follow-up of the amastigote-like characteristics (16, 24). Based on the drug sensitivity profile (Table 1) and the small-scale transmission electron microscopic study, our axenic amastigote model exhibited distinct promastigote-like characteristics, despite all precautions to prevent the culture from drifting back to the promastigote stage. Under light microscopy, the axenic appeared as immobile round stages with dense cell masses (diameter, about 2 m). Ultrastructurally, flagella protruding from the flagellar pocket were frequently observed (Fig. 1a and b). On the other hand, internalized axenic were clearly rounded, without protruding flagella, and contained megasome-like structures (Fig. 1c), which are membranebound compartments with lysosomal properties described for of Leishmania chagasi (1) and Leishmania mexicana complex (39). Apart from these ultrastructural indications, our in vitro results with Sb V and PX-6518 also confirm that the axenic behaved as promastigotes. A general consensus is that Sb V acts as a prodrug, exerting its parasiticidal effects through reduced Sb III, which is highly toxic to all stages (2, 7). Even though several reports describe selective activity of Sb V on established axenic (13, 32, 33), other researchers argue that cellular mechanisms are indeed required for the antileishmanial action of Sb V (12, 22, 28). Although the mechanism of action of PX-6518 is not yet known, our results indicate that its action is mainly cell mediated as well, as shown by its lack of efficacy in the axenic models (IC 50, 32 g/ml) and its high potency against intracellular (IC 50, 0.1 g/ml). Besides PMM, other cells, such as U937, J774, THP-1, and bone marrow-derived and human monocyte-derived macrophages, have been used in the intracellular amastigote model. Recently, it was shown that the macrophage cell type may influence the levels of activity that are obtained with current antileishmanial drugs, necessitating harmonization if results from different laboratories are to be compared (29). No differences in the IC 50 s of the reference drugs were found upon infection of PMM with metacyclic promastigotes, established axenic, or fresh spleen-derived ex vivo (Table 1). Amphotericin B showed slightly higher potency in the cellular model than in the axenic models, a difference that is likely related to accumulation in the phagolysosome. Miltefosine showed no clear trend to support any theory of differential sensitivity. Stibogluconate was active only in the cellular model, with a higher potency for the crystalline substance than for Pentostam (IC 50 s, 22.0 to 28.4 g Sb V /ml). A similar differential susceptibility was observed for PX-6518, but at a much higher potency (IC 50, 0.1 g/ml). The slightly lower activity after infection with metacyclic promastigotes (IC 50, 0.7 g/ml) may be related to incomplete intracellular transformation into. The latter phenomenon has been shown to occur frequently with clinical field isolates during their adaptation to in vitro culture and will affect the outcome of in vitro Sb resistance determinations (L. Maes, unpublished data). Overall, the results obtained in the present study are within the range of published IC 50 s for L. donovani strain L82 (10, 14, 30, 35): IC 50 s of 4.8 to 34.5 g Sb V /ml were reported for sodium stibogluconate against intracellular ; miltefosine exhibited IC 50 s of 0.18 to 13.6 M on promastigotes and 2.8 to 5.8 M on intracellular, while amphotericin B showed IC 50 s of to 0.15 M and to g/ml against promastigotes and intracellular, respectively. In summary, this study clearly demonstrates that the intracellular amastigote model is the only suitable approach for drug screening. The same cellular model is also required for the determination of resistance to Sb in view of its cell-mediated mode of action. For the latter, particular care must be taken to ascertain adequate intracellular transformation into, a problem frequently encountered with poorly infective field strains. If field strains are infective to hamsters, it may sometimes be helpful to use ex vivo as an infection inoculum for macrophages. For amphotericin B and miltefosine, the simpler axenic models could theoretically be used for resistance detection, but validation with a large set of field strains is still needed. ACKNOWLEDGMENTS This work was supported by a grant from FWO Flanders (project G ) and the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). M. Vermeersch is a BOF-NOI Ph.D. student at the University of Antwerp. P. Cos is a postdoctoral researcher awarded a grant by the Fund for Scientific Research (FWO Flanders, Belgium). REFERENCES 1. Alberio, S. O., S. S. Dias, F. P. Faria, R. A. Mortara, C. L. Barbieri, and E. F. Haapalainen Ultrastructural and cytochemical identification of megasome in Leishmania (Leishmania) chagasi. Parasitol. Res. 92: Ashutosh, S. Sundar, and N. Goyal Molecular mechanisms of antimony resistance in Leishmania. J. Med. Microbiol. 56: Berman, J Clinical status of agents being developed for leishmaniasis. Expert Opin. Investig. Drugs 14: Callahan, H. L., A. C. Portal, R. Devereaux, and M. Grogl An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41: Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar, and M. Boelaert Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5: Croft, S. L Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health 6: Croft, S. L., S. Sundar, and A. H. Fairlamb Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19: Cunningham, I New culture medium for maintenance of tsetse tissues and growth of trypanosomatids. J. Protozool. 24: Debrabant, A., M. B. Joshi, P. F. P. Pimenta, and D. M. Dwyer Generation of Leishmania donovani axenic : their growth and biological characteristics. Int. J. Parasitol. 34: del Rayo Camacho, M., J. D. Phillipson, S. L. Croft, P. Rock, S. J. Marshall, and P. L. Schiff In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei. Phytother. Res. 16: Drugs for Neglected Diseases Initiative Annual report, DNDi, Geneva, Switzerland.
5 VOL. 53, 2009 IN VITRO SUSCEPTIBILITIES OF LEISHMANIA STAGES Dube, A., N. Singh, S. Sundar, and N. Singh Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persists in in vitro and in vivo experimental models. Parasitol. Res. 96: Ephros, M., A. Bitnun, P. Shaked, E. Waldman, and D. Zilberstein Stage-specific activity of pentavalent antimony against Leishmania donovani axenic. Antimicrob. Agents Chemother. 43: Escobar, P., S. Matu, C. Marques, and S. L. Croft Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18- OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81: Fumarola, L., R. Spinelli, and O. Brandonisio In vitro assays for evaluation of drug activity against Leishmania spp. Res. Microbiol. 155: Gupta, N., N. Goyal, and A. K. Rastogi In vitro cultivation and characterization of axenic of Leishmania. Trends Parasitol. 17: Holzer, T. R., W. R. McMaster, and J. D. Forney Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived, and axenic in Leishmania mexicana. Mol. Biochem. Parasitol. 146: Kumar, D., A. Kulshrestha, R. Singh, and P. Salotra In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob. Agents Chemother. 53: Maes, L., D. Vanden Berghe, N. Germonprez, L. Quirijnen, P. Cos, N. De Kimpe, and L. Van Puyvelde In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob. Agents Chemother. 48: Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42: Mikus, J., and D. Steverding A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol. Int. 48: Mookerjee Basu, J., A. Mookerjee, P. Sen, S. Bhaumik, P. Sen, S. Banerjee, K. Naskar, S. K. Choudhuri, B. Saha, S. Raha, and S. Roy Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob. Agents Chemother. 50: Palatnik-de-Sousa, C. B Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: Pan, A. A., S. M. Duboise, S. Eperon, L. Rivas, V. Hodgkinson, Y. Traub- Cseko, and D. McMahon-Pratt Developmental life cycle of Leishmania cultivation and characterization of cultured extracellular. J. Eukaryot. Microbiol. 40: Pérez-Victoria, F. J., M. P. Sánchez-Cañete, K. Seifert, S. L. Croft, S. Sundar, S. Castanys, and F. Gamarro Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9: Rakotomanga, M., S. Blanc, K. Gaudin, P. Chaminade, and P. M. Loiseau Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 51: Rijal, S., F. Chappuis, R. Singh, P. A. Bovier, P. Acharya, B. M. Karki, M. L. Das, P. Desjeux, L. Loutan, and S. Koirala Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97: Roberts, W. L., J. D. Berman, and P. M. Rainey In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39: Seifert, K., P. Escobar, and S. Croft Activity of current anti-leishmanial drugs in in vitro macrophage-amastigote model is dependent on the host macrophage, poster 398. Fourth World Cong. Leishmaniasis, Lucknow, India, 3 to 7 February Seifert, K., F. J. Pérez-Victoria, M. Stettler, M. P. Sánchez-Cañete, S. Castanys, F. Gamarro, and S. L. Croft Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 30: Sereno, D., and J.-L. Lemesre Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41: Sereno, D., M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J. L. Lemesre Axenically grown of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42: Shaked-Mishan, P., N. Ulrich, M. Ephros, and D. Zilberstein Novel intracellular Sb V reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276: Shimony, O., and C. L. Jaffe Rapid fluorescent assay for screening drugs on Leishmania. J. Microbiol. Methods 75: Smith, A. C., V. Yardley, J. Rhodes, and S. L. Croft Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 44: Sundar, S., and H. W. Murray Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O. 83: Tavares, J., A. Ouaissi, P. K. Lin, A. Tomás, and A. Cordeiro-da-Silva Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic. Int. J. Parasitol. 35: Teixeira, M. C., R. de Jesus Santos, R. B. Sampaio, L. Pontes-de-Carvalho, and W. L. Dos-Santos A simple and reproducible method to obtain large numbers of axenic of different Leishmania species. Parasitol. Res. 88: Ueda-Nakamura, T., M. Attias, and W. de Souza Comparative analysis of megasomes in members of the Leishmania mexicana complex. Res. Microbiol. 158: Urbina, J. A Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans. R. Soc. Trop. Med. Hyg. 100:S9 S16.
A Novel Noninvasive Method for Diagnosis of Visceral Leishmaniasis by. rk39 Test in Sputum Samples
JCM Accepts, published online ahead of print on 0 June 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationMechanistic Studies of Pentamidine Analogs on Leishmania donovani Promastigotes
Mechanistic Studies of Pentamidine Analogs on Leishmania donovani Promastigotes Undergraduate Honors Thesis The Ohio State University, College of Pharmacy Division of Medicinal Chemistry and Pharmacognosy
More informationTransactions of the Royal Society of Tropical Medicine and Hygiene
Transactions of the Royal Society of Tropical Medicine and Hygiene 104 (2010) 225 229 Contents lists available at ScienceDirect Transactions of the Royal Society of Tropical Medicine and Hygiene journal
More informationAntimonial Resistance & Combination therapy in Indian Visceral Leishmaniasis. Shyam Sundar Banaras Hindu University Varanasi, India
Antimonial Resistance & Combination therapy in Indian Visceral Leishmaniasis Shyam Sundar Banaras Hindu University Varanasi, India History of the Current Epidemic in India & Antimony Resistance 6 Official
More informationReceived: 11 th August-2012 Revised: 14 th Sept-2012 Accepted: 16 th Sept-2012 Research article
Received: 11 th August-2012 Revised: 14 th Sept-2012 Accepted: 16 th Sept-2012 Research article IN VITRO ANTILEISHMANIAL ACTIVITY OF NYCTANTHES ARBOR-TRISTIS A MEDICINAL TREE Dr. Assistant Professor, Department
More informationEfficacies of Vesicular and Free Sodium Stibogluconate Formulations against Clinical Isolates of Leishmania donovani
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2001, p. 3555 3559 Vol. 45, No. 12 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.12.3555 3559.2001 Copyright 2001, American Society for Microbiology. All Rights
More information199 (M. A. Bioproducts, Walkersville, Md.). placed on 22-mm2 cover slips and incubated at 37 C in
INFECTION AND IMMUNITY, June 1981, p. 1249-1253 0019-9567/81/061249-05$02.00/0 Vol. 32, No. 3 Interaction of Leishmania donovani Promastigotes with Human Monocyte-Derived Macrophages: Parasite Entry, Intracellular
More informationThe Antileishmanial Agent Licochalcone A Interferes with the Function of Parasite Mitochondria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1995, p. 2742 2748 Vol. 39, No. 12 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology The Antileishmanial Agent Licochalcone A Interferes
More informationIranian J Parasitol: Vol. 8, No.3, July -Sep 2013, pp Iranian J Parasitol. Open access Journal at ijpa.tums.ac.ir
Iranian J Parasitol: Vol. 8, No.3, July -Sep 2013, pp.396-401 Iranian J Parasitol Tehran University of Medical Sciences Publication http:// tums.ac.ir Open access Journal at http:// ijpa.tums.ac.ir Iranian
More informationMedical Science. Jyoti Joshi, Sukhbir Kaur RESEARCH
Medical Science The International Weekly journal ISSN 2321 7359 EISSN 2321 7367 RESEARCH To investigate the protective efficacy and immunomodulatory potential of single dose combination of SSG along with
More informationAuthors Chappuis, François; Alirol, Emilie; Worku, Dagemlidet T; Mueller, Yolanda; Ritmeijer, Koert
MSF Field Research High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B Item type Article
More informationInt.J.Curr.Res.Aca.Rev.2017; 5(4):
International Journal of Current Research and Academic Review ISSN: 2347-3215 (Online) Volume 5 Number 4 (April-2017) Journal homepage: http://www.ijcrar.com doi: https://doi.org/10.20546/ijcrar.2017.504.014
More informationReferences for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines
6 (a) Visceral leishmaniasis disease burden. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004:27:305-18. Sundar S, Murray HW. Availability of miltefosine
More informationHAEMOFLAGELLATES. Dr. Anuluck Junkum Department of Parasitology Faculty of Medicine
HAEMOFLAGELLATES Dr. Anuluck Junkum Department of Parasitology Faculty of Medicine Objective Can describe the morphology, life cycle, pathology, diagnosis and prevention of Leishmania spp. and Trypanosoma
More informationDesign and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1597 1601 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1597 1601.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationGene Expression Analysis of the Mechanism of Natural Sb(V) Resistance in Leishmania donovani Isolates from Nepal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2005, p. 4616 4621 Vol. 49, No. 11 0066-4804/05/$08.00 0 doi:10.1128/aac.49.11.4616 4621.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationNanomedicine & Drug Delivery Systems Group Research Institute for Medicines and Pharmaceutical Sciences (imed.ul)
Faculty of Pharmacy of the University of Lisbon Nanomedicine & Drug Delivery Systems Group Research Institute for Medicines and Pharmaceutical Sciences (imed.ul) Leishmania in southern Europe. (Duiardin,
More informationMAJOR ARTICLE. visceral leishmaniasis; miltefosine; relapse; parasite drug resistance; Nepal.
MAJOR ARTICLE Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance Suman Rijal, 1 Bart Ostyn, 2 Surendra
More informationLaboratory diagnosis of Blood and tissue flagellates
Laboratory diagnosis of Blood and tissue flagellates (Leishmania and trypanosma) Sarah Alharbi Clinical Laboratory department Collage of Applied Medical Sciences King Saud University Leishmania and trypanosma:
More informationSingle-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
MAJOR ARTICLE Single-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study S. Sundar, 1 T. K. Jha, 2 C. P. Thakur, 3 M. Mishra, 4 V. P. Singh, 1 and R.
More informationon November 20, 2018 by guest
AAC Accepts, published online ahead of print on 13 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00985-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationIN VITRO ANTICANCER ACTIVITY OF FLOWER EXTRACTS OF COUROUPITA GUIANENSIS
CHAPTER 3 IN VITRO ANTICANCER ACTIVITY OF FLOWER EXTRACTS OF COUROUPITA GUIANENSIS 3. INTRODUCTION Plants are the basic source of knowledge of modern medicine. Almost all the parts of the plant, namely
More informationReview Article Drug Resistance in Visceral Leishmaniasis
Journal of Biomedicine and Biotechnology Volume 2010, Article ID 617521, 8 pages doi:10.1155/2010/617521 Review Article Drug Resistance in Visceral Leishmaniasis Helena C. Maltezou Department for Interventions
More informationUniversity of Dundee. Published in: Antimicrobial Agents and Chemotherapy DOI: /AAC Publication date: 2017
University of Dundee Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells
More informationDNA Transformation of Leishmania infantum Axenic Amastigotes and Their Use in Drug Screening
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2001, p. 1168 1173 Vol. 45, No. 4 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.4.1168 1173.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationProtozoa from tissues. Leishmania spp. Naegleria fowleri Toxoplasma gondii Trichomonas vaginalis Trypanosoma spp.
Protozoa from tissues Leishmania spp. Naegleria fowleri Toxoplasma gondii Trichomonas vaginalis Trypanosoma spp. Leishmaniasis Leishmania infantum, Leishmania donovani, in macrophages of man. Female sandflies:
More informationVisceral leishmaniasis: an endemic disease with global impact
Visceral leishmaniasis: an endemic disease with global impact Professor Olivier Lortholary, MD, PhD Department of Infectious and Tropical diseases Hôpital Necker-Enfants Malades Université Paris Descartes
More informationTherapeutic Options for Visceral Leishmaniasis
Drugs (2013) 73:1863 1888 DOI 10.1007/s40265-013-0133-0 REVIEW ARTICLE Therapeutic Options for Visceral Leishmaniasis Begoña Monge-Maillo Rogelio López-Vélez Published online: 30 October 2013 Ó The Author(s)
More informationNanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an in vitro and in vivo study
DARU Vol. 17, No. 4 2009 285 Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an in vitro and in vivo study *1 Mohebali M., 2 Rezayat M.M., 3
More informationMTS assay in A549 cells
Project: VIGO MTS assay in A549 cells Detection of cell viability/activity AUTHORED BY: DATE: Cordula Hirsch 20.01.2014 REVIEWED BY: DATE: Harald Krug 10.04.2014 APPROVED BY: DATE: DOCUMENT HISTORY Effective
More informationEpidemiological, clinical & pharmacological study of antimonyresistant visceral leishmaniasis in Bihar, India
Indian J Med Res 120, September 2004, pp 166-172 Epidemiological, clinical & pharmacological study of antimonyresistant visceral leishmaniasis in Bihar, India C.P. Thakur, S. Narayan* & A. Ranjan* Balaji
More informationSeries Editors Samuel J. Black, University of Massachusetts, Amherst, MA, US.A. J. Richard Seed, University of North Carolina, Chapel Hill, NC, US.A.
LEISHMANIA World Class Parasites VOLUME 4 Volumes in the World Class Parasites book series are written for researchers, students and scholars who enjoy reading about excellent research on problems of global
More informationBlood Smears Only 07 February Sample Preparation and Quality Control 12B A
NEW YORK STATE Parasitology Proficiency Testing Program Blood Smears Only 07 February 2012 The purpose of the New York State Proficiency Testing Program in the category of Parasitology Blood Smears Only
More informationEvaluation of rk28 antigen for serodiagnosis of visceral Leishmaniasis in India
ORIGINAL ARTICLE TROPICAL AND PARASITIC DISEASES Evaluation of rk8 antigen for serodiagnosis of visceral Leishmaniasis in India M. Vaish, A. Bhatia, S. G. Reed, J. Chakravarty and S. Sundar ) Department
More informationBlood Smears Only 6 October Sample Preparation and Quality Control 15B-K
NEW YORK STATE Parasitology Proficiency Testing Program Blood Smears Only 6 October 5 The purpose of the New York State Proficiency Testing Program in the category of Parasitology - Blood Smears Only is
More informationLeishmaniasis, Kala Azar(The Black Fever)
Leishmaniasis, Kala Azar(The Black Fever) By Lawrence Hall Etiologic agent Protist obligate intracellular parasite, Transmission Vectors Phylum: Euglenozoa (genus Leishmania) Over 21 species that infect
More informationReceived 13 June 2010/Returned for modification 30 July 2010/Accepted 12 August 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2010, p. 4699 4704 Vol. 54, No. 11 0066-4804/10/$12.00 doi:10.1128/aac.00809-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Reductions
More informationUltrastructural Study of Human Natural Killer CNK) Cell*)
Hiroshima Journal of Medical Sciences Vol. 31, No. 1, March, 1982 HJIM 31-6 31 Ultrastructural Study of Human Natural Killer CNK) Cell*) Yoshinori KAWAGUCHI, Eishi KITTAKA, Yoshito TANAKA, Takeo TANAKA
More informationOral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial
Tropical Medicine and International Health doi:10.1111/tmi.12015 volume 18 no 1 pp 96 100 january 2013 Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial Shyam Sundar 1,
More informationLeishmaniasis impact and treatment access
REVIEW 10.1111/j.1469-0691.2011.03635.x Leishmaniasis impact and treatment access M. den Boer, D. Argaw, J. Jannin and J. Alvar Leishmaniasis Control Programme, WHO/IDM. Av. Appia, Geneva, Switzerland
More informationLeishmaniasis chemotherapy challenges and opportunities
REVIEW 10.1111/j.1469-0691.2011.03630.x Leishmaniasis chemotherapy challenges and opportunities S. L. Croft 1 and P. Olliaro 2,3 1) Faculty of Infectious and Tropical Diseases, London School of Hygiene
More informationKala-Azar- Treatment Update
JOURNAL OF ADVANCES IN MEDICINE (JAM) DOI: 10.5958/2319-4324.2016.00002.X REVIEW PAPER Kala-Azar- Treatment Update Anup Singh Associate Professor, Department of Medicine, Institute of Medical Sciences,
More informationB16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small cell lung cancer
Electronic Supplementary Material (ESI) for ChemComm. This journal is The Royal Society of Chemistry 2017 Experimental Methods Cell culture B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small
More informationEffect of hydroxyurea on the intracellular multiplication of. gondii, Leishmania amazonensis and Trypanosoma
Brazilian Journal of Medical and Biological Research (2003) 36: 65-69 ISSN 0100-879X Short Communication 65 Effect of hydroxyurea on the intracellular multiplication of Toxoplasma gondii, Leishmania amazonensis
More informationThe Most Common Parasitic Infections In Yemen. Medical Parasitology
The Most Common Parasitic Infections In Yemen Medical Parasitology ﻓﺎﯾز اﻟﺧوﻻﻧﻲ / د 2 : is a vector-borne disease that transmitted by sandflies and caused by obligate intracellular protozoa of the genus
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 04 Jan 2019 20:47:10 GMT) CTRI Number Last Modified On 25/04/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationElimination of VL in the Indian subcontinent is it achievable?
Elimination of VL in the Indian subcontinent is it achievable? P Das Rajendra Memorial Research Institute, Patna Jorge Alvar DNDi, Geneva Bhawna Sharma DNDi, India Leishmaniasis 350 million at risk worldwide
More informationLeishmaniasis is a cosmopolitan disease
Pakistan J. Zool., vol. 36(1), pp. 45-52, 24. Anti-Leishmanial Drug Delivery: Acetylated LDL as A Site-Specific Delivery Ligand AKRAM SHAH * AND DAVID HART Life Sciences Department, School of Life, Basic
More informationAperito Journal of Bacteriology, Virology and Parasitology. Therapeutic Potential of Nanoparticulate System for Treatment. of Protozoan Infection
Aperito Journal of Bacteriology, Virology and Parasitology Received: Sep 19, 2014 Accepted: Oct 08, 2014 Published: Oct 12, 2014 http://dx.doi.org/10.14437/ajbvp-1-102 Editorial Arghya Bandyopadhyay, Aperito
More informationWelcome to the Jungle! Dr Aileen Oon, 2017 Microbiology Registrar
Welcome to the Jungle! Dr Aileen Oon, 2017 Microbiology Registrar AA 55M presented with sores on left olecranon and umbilical area Umbilical sores present for 3 weeks Left olecranon lesions for 1 week
More informationSMe. Me NITROIMIDAZOLES FOR VISCERAL LEISHMANIASIS FEXINIDAZOLE AND VL-2098 SHYAM SUNDAR
SMe O 2 CH 2 O Me ITROIMIDAZOLES FOR VISCERAL LEISHMAIASIS FEXIIDAZOLE AD VL-2098 SHYAM SUDAR Target Product Profile for a CE Optimal Target Profile Target Label VL and PKDL VL Spp All species L. donavani
More informationMorphological forms of hemoflagellates
Parasitology Lecture: 1 Hemoflagellates (blood and tissue flagellates) *Classification: - Sub-kingdom: Protozoa -Phylum: Sarcomastigophora -Sub-phylum: Mastigiphora -Class: Zoomastigophora د. رائد *Flagellates
More informationPharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs. Ethiopia
Pharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs in HIV/VL coinfected patients in Ethiopia Anke E. Kip, Séverine Blesson, Fabiana Alves, Robert Kimutai, Peninah
More informationLaboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Srivastava et al. Parasites & Vectors (2017) 10:49 DOI 10.1186/s13071-017-1969-z RESEARCH Open Access Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India Saumya Srivastava,
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationResearch Article Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis
ISRN Parasitology, Article ID 548010, 4 pages http://dx.doi.org/10.1155/2014/548010 Research Article Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis Shyam Sundar,
More informationDrug resistance in Indian visceral leishmaniasis
Tropical Medicine and International Health volume6no11pp849±854november2001 Drug resistance in Indian visceral leishmaniasis Shyam Sundar Kala-azar Medical Research Centre, Banaras Hindu University, Varanasi,
More informationTitle: Treatment failure and miltefosine susceptibility in dermal leishmaniasis
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01023-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Title:
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 22 by the Massachusetts Medical Society VOLUME 347 N OVEMBER 28, 22 NUMBER 22 ORAL MILTEFOSINE FOR INDIAN VISCERAL LEISHMANIASIS SHYAM SUNDAR, M.D., T.K. JHA,
More informationTreatment of Cutaneous Leishmaniasis with Allopurinol and Stibogluconate
165 Treatment of Cutaneous Leishmaniasis with Allopurinol and S. Martinez, M. Gonzalez, and M. E. Vernaza From the Department of Internal Medicine, University of Cauca, Popayan, and the University Hospital
More informationBiochemical and Biophysical Research Communications
Biochemical and Biophysical Research Communications 399 (2010) 429 433 Contents lists available at ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
More informationReview Article. Management of visceral leishmaniasis: Indian perspective
Review Article www.jpgmonline.com Management of visceral leishmaniasis: Indian perspective S. Agrawal, M. Rai, S. Sundar Department of Medicine, Institute of Medical Sciences, Banaras Hindu University,
More informationInvestigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs
1032 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(8): 1032-1038, December 2011 Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs
More informationTherapy of Visceral Leishmaniasis Due to Leishmania infantum: Experimental Assessment of Efficacy of AmBisome
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1996, p. 1214 1218 Vol. 40, No. 5 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Therapy of Visceral Leishmaniasis Due to Leishmania
More informationTherapy of Visceral Leishmaniasis Due to Leishmania infantum: Experimental Assessment of Efficacy of AmBisome
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1996, p. 1214 1218 Vol. 40, No. 5 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Therapy of Visceral Leishmaniasis Due to Leishmania
More informationPharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis
J Antimicrob Chemother 216; 71: 1892 1898 doi:1.193/jac/dkw89 Advance Access publication 15 April 216 Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis
More informationEfficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
MAJOR ARTICLE Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use Shyam Sundar, 1,a Anup Singh, 1,a Madhukar Rai, 1 Vijay K. Prajapati, 1 Avinash K. Singh,
More informationVisceral Leishmaniasis combination therapies
Best Science for the Most Neglected From patient needs to implementation of new treatments Visceral Leishmaniasis combination therapies Shyam Sundar Institute of Medical Sciences Banaras Hindu University
More informationVisceral leishmaniasis: what are the needs for diagnosis, treatment and control?
EVALUATING DIAGNOSTICS Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? François Chappuis*, Shyam Sundar, Asrat Hailu, Hashim Ghalib, Suman Rijal #, Rosanna W. Peeling,
More informationVisceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?
Viewpoints Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent? Meghan R. Perry 1, Susan Wyllie 1, Vijay Kumar Prajapati 2, Joerg
More informationLeishmaniasis Direct Agglutination Test: Using Pictorials as Training Materials to Reduce Inter-Reader Variability and Improve Accuracy
Leishmaniasis Direct Agglutination Test: Using Pictorials as Training Materials to Reduce Inter-Reader Variability and Improve Accuracy Emily R. Adams 1 *, Diane Jacquet 2, Gerard Schoone 1, Kamlesh Gidwani
More informationBIO Parasitology Spring 2009
BIO 475 - Parasitology Spring 2009 Stephen M. Shuster Northern Arizona University http://www4.nau.edu/isopod Lecture 5 Discovery of the Disease In 1924 the Kala-Azar Commission noted that the distribution
More informationAuthor Manuscript Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections
More informationLeishmaniasis: A forgotten disease among neglected people
ISPUB.COM The Internet Journal of Health Volume 11 Number 2 Leishmaniasis: A forgotten disease among neglected people Y Homsi, G Makdisi Citation Y Homsi, G Makdisi. Leishmaniasis: A forgotten disease
More informationLeishmaniasis: Challenges for Vaccine Development
Leishmaniasis: Challenges for Vaccine Development Steven G. Reed Infectious Disease Research Institute Seattle IDRI Goals: Leishmaniasis To improve existing vaccines for use in therapy and prevention.
More informationPOST KALA-AZAR DERMAL LEISHMANIASIS WITH ULCERATION ON FOOT: AN ATYPICAL CASE PRESENTATION SUCCESSFULLY TREATED WITH MILTEFOSINE
American Journal of Infectious Diseases 10 (2): 50-55, 2014 ISSN: 1553-6203 2014 Science Publication doi:10.3844/ajidsp.2014.50.55 Published Online 10 (2) 2014 (http://www.thescipub.com/ajid.toc) POST
More informationby author Drug Therapy in African Visceral Leishmaniasis 28th ECCMID Conference, Madrid, Spain 21 April 2018
Drug Therapy in African Visceral Leishmaniasis 28th ECCMID Conference, Madrid, Spain 21 April 2018 Dr. Monique Wasunna, Director, DNDi Africa Regional Office Presentation Outline 1 2 4 5 Introduction leishmaniasis
More information18 : 1. Shyam Sundar, Anup Singh, Arun Shah, Varanasi EPIDEMIOLOGY: DIAGNOSIS OF VL:
18 : 1 Visceral leishmaniasis-current scenario Visceral leishmaniasis (VL) is a systemic disease that is fatal if left untreated and is caused by an obligate intracellular protozoan parasite of genus leishmania.
More informationLD Bodies From Blood Buffy Coat: an Easy Approach for Definitive Diagnosis of Visceral Leishmaniasis
Bangladesh J Med Microbiol 2007; 01 (02): 43-47 Bangladesh Society of Medical Microbiologists Original Article LD Bodies From Blood Buffy Coat: an Easy Approach for Definitive Diagnosis of Visceral Leishmaniasis
More informationRecombinant Trypsin, Animal Origin Free
Recombinant Trypsin, Animal Origin Free PRODUCT INFORMATION: BioGenomics r-trypsin powder is ready to use, animal origin free optimized for cell culture applications. It is derived by r-dna technology.
More informationter Horst, Rachel; Tefera, Tewodros; Assefa, Gessesse; Ebrahim, Abdurazik Z; Davidson, Robert N; Ritmeijer, Koert
MSF Field Research Field evaluation of rk39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia Item
More informationApplication for Inclusion of MILTEFOSINE on WHO Model List of Essential Medicines:
Application for Inclusion of MILTEFOSINE on WHO Model List of Essential Medicines: Comments re Feb 2011 reviews of the v 2010 application February 23, 2011 1. The application and its review In v 2010,
More informationHexadecylphosphocholine: Oral Treatment of Visceral Leishmaniasis in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1992, p. 1630-1634 Vol. 36, No. 8 0066-4804/92/081630-05$02.00/0 Hexadecylphosphocholine: Oral Treatment of Visceral Leishmaniasis in Mice ARMIN KUHLENCORD,1*
More informationShort-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment
MAJOR ARTICLE Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment Shyam Sundar, Neha Agrawal, Rakesh Arora, Dipti Agarwal, Madhukar Rai, and Jaya Chakravarty
More informationPost Kala-azar Dermal Leishmaniasis (PKDL) from the field to the cellular and the subcellular levels
Post Kala-azar Dermal Leishmaniasis (PKDL) from the field to the cellular and the subcellular levels A M EL Hassan Institute of Endemic Diseases University of Khartoum Introduction PKDL is a VL related
More informationCellular Effects of Reversed Amidines on Trypanosoma cruzi
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2007, p. 3803 3809 Vol. 51, No. 11 0066-4804/07/$08.00 0 doi:10.1128/aac.00047-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Cellular
More informationMTS assay in THP-1 cells
Project: VIGO MTS assay in THP-1 cells Detection of cell viability/activity AUTHORED BY: DATE: Cordula Hirsch 20.01.2014 REVIEWED BY: DATE: Harald Krug 10.04.2014 APPROVED BY: DATE: DOCUMENT HISTORY Effective
More informationIn Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmaniainfantum
Journal of Parasitology Research Volume 2012, Article ID 756568, 7 pages doi:10.1155/2012/756568 Research Article In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmaniainfantum
More informationAppendix A: Preparation of Media and Chemicals. Malt Extract Agar (MEA) weighing g was dissolved in 400 ml of distilled water
Appendix A: Preparation of Media and Chemicals Preparation of Malt Extract Agar (MEA) Malt Extract Agar (MEA) weighing 13.44 g was dissolved in 400 ml of distilled water in an Erlenmeyer flask using a
More informationSingle-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
The new england journal of medicine original article Single-Dose Liposomal for Visceral Leishmaniasis in India Shyam Sundar, M.D., Jaya Chakravarty, M.D., Dipti Agarwal, M.D., Madhukar Rai, M.D., and Henry
More informationControl of leishmaniasis
SIXTIETH WORLD HEALTH ASSEMBLY A60/10 Provisional agenda item 12.3 22 March 2007 Control of leishmaniasis Report by the Secretariat BACKGROUND 1. Leishmaniasis is endemic in 88 countries in the world and
More informationINSTRUCTIONS Pierce Primary Cardiomyocyte Isolation Kit
INSTRUCTIONS Pierce Primary Cardiomyocyte Isolation Kit 88281 Number Description 88281 Pierce Primary Cardiomyocyte Isolation Kit, contains sufficient reagents to isolate cardiomyocytes from 50 neonatal
More informationVisceral leishmaniasis - current therapeutic modalities
Review Article Indian J Med Res 123, March 2006, pp 345-352 Visceral leishmaniasis - current therapeutic modalities Shyam Sundar & Mitali Chatterjee* Kala-azar Medical Research Center, Department of Medicine,
More informationMueller, Y; Mbulamberi, Dawson B; Odermatt, Peter; Hoffmann, Axel; Loutan, Louis; Chappuis, François
MSF Field Research Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Authors Citation DOI Journal Rights Mueller, Y; Mbulamberi, Dawson B; Odermatt, Peter; Hoffmann,
More informationVisceral Leishmaniasis in the Indian Subcontinent: Modelling Epidemiology and Control
Visceral Leishmaniasis in the Indian Subcontinent: Modelling Epidemiology and Control Anette Stauch 1., Ram Rup Sarkar 2., Albert Picado 3, Bart Ostyn 3, Shyam Sundar 4, Suman Rijal 5, Marleen Boelaert
More informationPost Kala-azar Dermal Leishmaniasis (PKDL) In vivo veritas
Post Kala-azar Dermal Leishmaniasis (PKDL) In vivo veritas Mitali Chatterjee Dept. of Pharmacology, Institute of PG Medical Education & Research, Kolkata 26 th August, 2016 1 st February 2017; Health
More informationEVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES
ORIGINAL REPORT EVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES J. Esmaeili 1, M. Mohebali 1*, G. H. Edrissian 1, S. M. Rezayat 2, M. Ghazi-Khansari 2 and
More informationDa un ricerca sul mechanismo della miltefosine sul promastigote di leishmania donovani, pubblicato nel 2004 risulta la prova che miltefosine è un
Da un ricerca sul mechanismo della miltefosine sul promastigote di leishmania donovani, pubblicato nel 2004 risulta la prova che miltefosine è un potente farmaco orale contro la leishmania viscerale. il
More informationInternational Journal Of Recent Scientific Research
International Journal Of Recent Scientific Research ISSN: 0976-3031 Volume: 7(5) May -2016 NEW ERA ABOUT TREATMENT - EVOLUATION OF ANTICANCER PROPERTIES OF EVERGREEN MEDICINAL PLANT ANNONA MURICATA (GRAVIOLA)
More information8. CHAPTER IV. ANTICANCER ACTIVITY OF BIOSYNTHESIZED SILVER NANOPARTICLES
8. CHAPTER IV. ANTICANCER ACTIVITY OF BIOSYNTHESIZED SILVER NANOPARTICLES 8.1. Introduction Nanobiotechnology, an emerging field of nanoscience, utilizes nanobased-systems for various biomedical applications.
More information